Comparative Pharmacology
Head-to-head clinical analysis: PLATINOL versus PLATINOL AQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLATINOL versus PLATINOL AQ.
PLATINOL vs PLATINOL-AQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cisplatin forms intrastrand crosslinks with DNA, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Platinol-AQ (cisplatin) exerts its cytotoxic effects by forming intrastrand and interstrand DNA crosslinks, thereby inhibiting DNA replication and transcription, leading to apoptosis.
50-100 mg/m² IV every 3-4 weeks as a single dose or 15-20 mg/m² IV daily for 5 days every 3-4 weeks.
50-100 mg/m² intravenously every 3-4 weeks, or 15-20 mg/m² intravenously daily for 5 days every 3-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 20-30 hours (biphasic: initial t1/2 20-30 min; post-distribution t1/2 5-10 days for protein-bound platinum). Prolonged in renal impairment.
Terminal elimination half-life of total platinum is 20-30 hours (mean ~24 hours) in patients with normal renal function; ultrafilterable (active) cisplatin has an initial half-life of 20-30 minutes and a terminal half-life of 48-72 hours due to prolonged tissue binding.
Renal: >90% unchanged; biliary/fecal <10%
Renal excretion of unchanged cisplatin; 15-50% of total platinum is excreted within 24 hours, and 20-80% within 72 hours. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Platinum-based Chemotherapy
Platinum-based Chemotherapy